Table 2.
Subgroup analyses.
| Subgroup | Enrolled studies (ID numbers) | SMD | 95% CI | I 2 |
|---|---|---|---|---|
| Overall | 1, 2, 4, 5, 7, 11, 12, 14, 16, 17, 19, 21, 24, 25, 28, 29, 31, 32, 33 | 0.27 | 0.23–0.31 | 94.4% |
| Jadad score | ||||
| High | 4, 5, 16, 17, 25, 29, 32 | 0.46 | 0.37; 0.55 | 93.3% |
| Intermediate | 7, 12, 19, 24, 28 | 0.23 | 0.15; 0.30 | 94.3% |
| Low | 1, 2, 11, 14, 21, 31, 33 | 0.24 | 0.18; 0.29 | 96.0% |
| Control group* | ||||
| Waiting list | 1, 4, 5, 7, 12, 14, 25, 28, 31 | 0.22 | 0.18; 0.27 | 95.8% |
| Other controls | 2, 11, 19, 21, 24, 29, 32, 33 | 0.47 | 0.38; 0.55 | 93.7% |
| Condition | ||||
| Cancer | 1, 4, 7, 12, 14, 19, 25, 28, 29, 31 | 0.20 | 0.15; 0.24 | 94.3% |
| Noncancer | 2, 5, 11, 16, 17, 21, 24, 32, 33 | 0.46 | 0.24; 0.67 | 76.6% |